<DOC>
	<DOC>NCT01758198</DOC>
	<brief_summary>The purpose of this study is to compare the clinical efficacy including joint damage progression and safety of Abatacept plus Methotrexate (MTX) to placebo plus MTX.</brief_summary>
	<brief_title>Abatacept Post-marketing Clinical Study in Japan</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis, Rheumatoid</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Abatacept</mesh_term>
	<criteria>MTX inadequate responder Biologic Naïve Functional class I, II or III ≥6 swollen and ≥6 tender joints Creactive protein (CRP) ≥2.0mg/dl or erythrocyte sedimentation rate (ESR) ≥28 mm/hr Anticyclic citrullinated peptide (CCP) antibody positive Have erosion Any other rheumatic disease Active angiitis on main organs excluding rheumatoid nodule</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>